LABCORP HOLDINGS INC. — Director's Dealing 2020

Apr 7, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LABORATORY CORP OF AMERICA HOLDINGS (LH)
CIK: 0000920148
Period of Report: 2020-04-03

Reporting Person: Kirchgraber Paul R (CEO, Covance Drug Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-04-03	Common Stock	M	1010	—	Acquired	8459	Direct
2020-04-03	Common Stock	F	372	$113.31	Disposed	8087	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-04-03	Restricted Stock Unit	$	M	1010	Disposed		Common Stock (1010)	Direct

Footnotes

F1: Stock withholding to satisfy tax withholding obligations.

F2: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on April 3, 2019.

F4: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.